-
1
-
-
30144443996
-
Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001
-
Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006; 107:265-76.
-
(2006)
Blood.
, vol.107
, pp. 265-276
-
-
Morton, L.M.1
Wang, S.S.2
Devesa, S.S.3
Hartge, P.4
Weisenburger, D.D.5
Linet, M.S.6
-
2
-
-
77952477025
-
Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era
-
Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M, Loeffler M. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 2010; 28:2373-80.
-
(2010)
J Clin Oncol.
, vol.28
, pp. 2373-2380
-
-
Ziepert, M.1
Hasenclever, D.2
Kuhnt, E.3
Glass, B.4
Schmitz, N.5
Pfreundschuh, M.6
Loeffler, M.7
-
3
-
-
0037142053
-
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma
-
Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346:1937-47.
-
(2002)
N Engl J Med.
, vol.346
, pp. 1937-1947
-
-
Rosenwald, A.1
Wright, G.2
Chan, W.C.3
Connors, J.M.4
Campo, E.5
Fisher, R.I.6
Gascoyne, R.D.7
Muller-Hermelink, H.K.8
Smeland, E.B.9
Giltnane, J.M.10
Hurt, E.M.11
Zhao, H.12
Averett, L.13
-
4
-
-
18244409933
-
Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning
-
Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguiar RC, Gaasenbeek M, Angelo M, Reich M, Pinkus GS, Ray TS, Koval MA, Last KW, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 2002; 8:68-74.
-
(2002)
Nat Med.
, vol.8
, pp. 68-74
-
-
Shipp, M.A.1
Ross, K.N.2
Tamayo, P.3
Weng, A.P.4
Kutok, J.L.5
Aguiar, R.C.6
Gaasenbeek, M.7
Angelo, M.8
Reich, M.9
Pinkus, G.S.10
Ray, T.S.11
Koval, M.A.12
Last, K.W.13
-
5
-
-
0034598746
-
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
-
Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403:503-11.
-
(2000)
Nature.
, vol.403
, pp. 503-511
-
-
Alizadeh, A.A.1
Eisen, M.B.2
Davis, R.E.3
Ma, C.4
Lossos, I.S.5
Rosenwald, A.6
Boldrick, J.C.7
Sabet, H.8
Tran, T.9
Yu, X.10
Powell, J.I.11
Yang, L.12
Marti, G.E.13
-
6
-
-
84055176499
-
Chromosomal instability substantiates poor prognosis in patients with diffuse large B-cell lymphoma
-
Bakhoum SF, Danilova OV, Kaur P, Levy NB, Compton DA. Chromosomal instability substantiates poor prognosis in patients with diffuse large B-cell lymphoma. Clin Cancer Res. 2011; 17:7704-11.
-
(2011)
Clin Cancer Res.
, vol.17
, pp. 7704-7711
-
-
Bakhoum, S.F.1
Danilova, O.V.2
Kaur, P.3
Levy, N.B.4
Compton, D.A.5
-
7
-
-
80052269038
-
Analysis of the coding genome of diffuse large B-cell lymphoma
-
Pasqualucci L, Trifonov V, Fabbri G, Ma J, Rossi D, Chiarenza A, Wells VA, Grunn A, Messina M, Elliot O, Chan J, Bhagat G, Chadburn A, et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet. 2011; 43:830-7.
-
(2011)
Nat Genet.
, vol.43
, pp. 830-837
-
-
Pasqualucci, L.1
Trifonov, V.2
Fabbri, G.3
Ma, J.4
Rossi, D.5
Chiarenza, A.6
Wells, V.A.7
Grunn, A.8
Messina, M.9
Elliot, O.10
Chan, J.11
Bhagat, G.12
Chadburn, A.13
-
8
-
-
84867088456
-
Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone
-
Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S, Scott DW, Tan KL, Steidl C, Sehn LH, Chan WC, Iqbal J, Meyer PN, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012; 30:3452-9.
-
(2012)
J Clin Oncol.
, vol.30
, pp. 3452-3459
-
-
Johnson, N.A.1
Slack, G.W.2
Savage, K.J.3
Connors, J.M.4
Ben-Neriah, S.5
Rogic, S.6
Scott, D.W.7
Tan, K.L.8
Steidl, C.9
Sehn, L.H.10
Chan, W.C.11
Iqbal, J.12
Meyer, P.N.13
-
9
-
-
84879385620
-
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
-
Hu S, Xu-Monette ZY, Tzankov A, Green T, Wu L, Balasubramanyam A, Liu WM, Visco C, Li Y, Miranda RN, Montes-Moreno S, Dybkaer K, Chiu A, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013; 121:4021-31.
-
(2013)
Blood.
, vol.121
, pp. 4021-4031
-
-
Hu, S.1
Xu-Monette, Z.Y.2
Tzankov, A.3
Green, T.4
Wu, L.5
Balasubramanyam, A.6
Liu, W.M.7
Visco, C.8
Li, Y.9
Miranda, R.N.10
Montes-Moreno, S.11
Dybkaer, K.12
Chiu, A.13
-
10
-
-
84884944145
-
MYC protein expression and genetic alterations have prognostic impact in diffuse large B-cell lymphoma treated with immunochemotherapy
-
Valera A, López-Guillermo A, Cardesa-Salzmann T, Climent F, González-Barca E, Mercadal S, Espinosa I, Novelli S, Briones J, Mate JL, Salamero O, Sancho JM, Arenillas L, et al. MYC protein expression and genetic alterations have prognostic impact in diffuse large B-cell lymphoma treated with immunochemotherapy. Haematologica. 2013; 98:1554-62.
-
(2013)
Haematologica.
, vol.98
, pp. 1554-1562
-
-
Valera, A.1
López-Guillermo, A.2
Cardesa-Salzmann, T.3
Climent, F.4
González-Barca, E.5
Mercadal, S.6
Espinosa, I.7
Novelli, S.8
Briones, J.9
Mate, J.L.10
Salamero, O.11
Sancho, J.M.12
Arenillas, L.13
-
11
-
-
40449120350
-
An oncogene-induced DNA damage model for cancer development
-
Halazonetis TD, Gorgoulis VG, Bartek J. An oncogene-induced DNA damage model for cancer development. Science. 2008; 319:1352-5.
-
(2008)
Science.
, vol.319
, pp. 1352-1355
-
-
Halazonetis, T.D.1
Gorgoulis, V.G.2
Bartek, J.3
-
13
-
-
77958498222
-
The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer
-
Smith J, Tho LM, Xu N, Gillespie DA. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res. 2010; 108:73-112.
-
(2010)
Adv Cancer Res.
, vol.108
, pp. 73-112
-
-
Smith, J.1
Tho, L.M.2
Xu, N.3
Gillespie, D.A.4
-
14
-
-
55249116558
-
Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin
-
Kinner A, Wu W, Staudt C, Iliakis G. Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. Nucleic Acids Res. 2008; 36:5678-94.
-
(2008)
Nucleic Acids Res.
, vol.36
, pp. 5678-5694
-
-
Kinner, A.1
Wu, W.2
Staudt, C.3
Iliakis, G.4
-
15
-
-
84873388790
-
γ-H2AX foci formation as a pharmacodynamic marker of DNA damage produced by DNA cross-linking agents: results from 2 phase I clinical trials of SJG-136 (SG2000)
-
Wu J, Clingen PH, Spanswick VJ, Mellinas-Gomez M, Meyer T, Puzanov I, Jodrell D, Hochhauser D, Hartley JA. γ-H2AX foci formation as a pharmacodynamic marker of DNA damage produced by DNA cross-linking agents: results from 2 phase I clinical trials of SJG-136 (SG2000). Clin Cancer Res. 2013; 19:721-30.
-
(2013)
Clin Cancer Res.
, vol.19
, pp. 721-730
-
-
Wu, J.1
Clingen, P.H.2
Spanswick, V.J.3
Mellinas-Gomez, M.4
Meyer, T.5
Puzanov, I.6
Jodrell, D.7
Hochhauser, D.8
Hartley, J.A.9
-
17
-
-
82955203422
-
Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors
-
Murga M, Campaner S, Lopez-Contreras AJ, Toledo LI, Soria R, Montaña MF, D'Artista L, Schleker T, Guerra C, Garcia E, Barbacid M, Hidalgo M, Amati B, et al. Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. Nat Struct Mol Biol. 2011; 18:1331-5.
-
(2011)
Nat Struct Mol Biol.
, vol.18
, pp. 1331-1335
-
-
Murga, M.1
Campaner, S.2
Lopez-Contreras, A.J.3
Toledo, L.I.4
Soria, R.5
Montaña, M.F.6
D'Artista, L.7
Schleker, T.8
Guerra, C.9
Garcia, E.10
Barbacid, M.11
Hidalgo, M.12
Amati, B.13
-
18
-
-
81255143440
-
Therapeutic implications for the induced levels of Chk1 in Myc-expressing cancer cells
-
Höglund A, Nilsson LM, Muralidharan SV, Hasvold LA, Merta P, Rudelius M, Nikolova V, Keller U, Nilsson JA. Therapeutic implications for the induced levels of Chk1 in Myc-expressing cancer cells. Clin Cancer Res. 2011; 17:7067-79.
-
(2011)
Clin Cancer Res.
, vol.17
, pp. 7067-7079
-
-
Höglund, A.1
Nilsson, L.M.2
Muralidharan, S.V.3
Hasvold, L.A.4
Merta, P.5
Rudelius, M.6
Nikolova, V.7
Keller, U.8
Nilsson, J.A.9
-
19
-
-
84884273290
-
DNA repair genes are selectively mutated in diffuse large B cell lymphomas
-
De Miranda NF, Peng R, Georgiou K, Wu C, Falk Sörqvist E, Berglund M, Chen L, Gao Z, Lagerstedt K, Lisboa S, Roos F, van Wezel T, Teixeira MR, et al. DNA repair genes are selectively mutated in diffuse large B cell lymphomas. J Exp Med. 2013; 210:1729-42.
-
(2013)
J Exp Med.
, vol.210
, pp. 1729-1742
-
-
De Miranda, N.F.1
Peng, R.2
Georgiou, K.3
Wu, C.4
Falk Sörqvist, E.5
Berglund, M.6
Chen, L.7
Gao, Z.8
Lagerstedt, K.9
Lisboa, S.10
Roos, F.11
van Wezel, T.12
Teixeira, M.R.13
-
20
-
-
79959978644
-
Unleashing Chk1 in cancer therapy
-
Carrassa L, Damia G. Unleashing Chk1 in cancer therapy. Cell Cycle. 2011; 10:2121-8.
-
(2011)
Cell Cycle.
, vol.10
, pp. 2121-2128
-
-
Carrassa, L.1
Damia, G.2
-
21
-
-
84871234067
-
Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias
-
Karp JE, Thomas BM, Greer JM, Sorge C, Gore SD, Pratz KW, Smith BD, Flatten KS, Peterson K, Schneider P, Mackey K, Freshwater T, Levis MJ, et al. Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias. Clin Cancer Res. 2012; 18:6723-31.
-
(2012)
Clin Cancer Res.
, vol.18
, pp. 6723-6731
-
-
Karp, J.E.1
Thomas, B.M.2
Greer, J.M.3
Sorge, C.4
Gore, S.D.5
Pratz, K.W.6
Smith, B.D.7
Flatten, K.S.8
Peterson, K.9
Schneider, P.10
Mackey, K.11
Freshwater, T.12
Levis, M.J.13
-
22
-
-
53349156857
-
Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1
-
Blasina A, Hallin J, Chen E, Arango ME, Kraynov E, Register J, Grant S, Ninkovic S, Chen P, Nichols T, O'Connor P, Anderes K. Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1. Mol Cancer Ther. 2008; 7:2394-404.
-
(2008)
Mol Cancer Ther.
, vol.7
, pp. 2394-2404
-
-
Blasina, A.1
Hallin, J.2
Chen, E.3
Arango, M.E.4
Kraynov, E.5
Register, J.6
Grant, S.7
Ninkovic, S.8
Chen, P.9
Nichols, T.10
O'Connor, P.11
Anderes, K.12
-
23
-
-
68049107474
-
PF-00477736 mediates checkpoint kinase 1 signaling pathway and potentiates docetaxel-induced efficacy in xenografts
-
Zhang C, Yan Z, Painter CL, Zhang Q, Chen E, Arango ME, Kuszpit K, Zasadny K, Hallin M, Hallin J, Wong A, Buckman D, Sun G, et al. PF-00477736 mediates checkpoint kinase 1 signaling pathway and potentiates docetaxel-induced efficacy in xenografts. Clin Cancer Res. 2009; 15:4630-40.
-
(2009)
Clin Cancer Res.
, vol.15
, pp. 4630-4640
-
-
Zhang, C.1
Yan, Z.2
Painter, C.L.3
Zhang, Q.4
Chen, E.5
Arango, M.E.6
Kuszpit, K.7
Zasadny, K.8
Hallin, M.9
Hallin, J.10
Wong, A.11
Buckman, D.12
Sun, G.13
-
24
-
-
84864877535
-
The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells
-
Landau HJ, McNeely SC, Nair JS, Comenzo RL, Asai T, Friedman H, Jhanwar SC, Nimer SD, Schwartz GK. The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells. Mol Cancer Ther. 2012; 11:1781-8.
-
(2012)
Mol Cancer Ther.
, vol.11
, pp. 1781-1788
-
-
Landau, H.J.1
McNeely, S.C.2
Nair, J.S.3
Comenzo, R.L.4
Asai, T.5
Friedman, H.6
Jhanwar, S.C.7
Nimer, S.D.8
Schwartz, G.K.9
-
25
-
-
84865210853
-
ATM/ATR checkpoint activation downregulates CDC25C to prevent mitotic entry with uncapped telomeres
-
Thanasoula M, Escandell JM, Suwaki N, Tarsounas M. ATM/ATR checkpoint activation downregulates CDC25C to prevent mitotic entry with uncapped telomeres. EMBO J. 2012; 31:3398-410.
-
(2012)
EMBO J.
, vol.31
, pp. 3398-3410
-
-
Thanasoula, M.1
Escandell, J.M.2
Suwaki, N.3
Tarsounas, M.4
-
26
-
-
79957916529
-
Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition
-
Parsels LA, Qian Y, Tanska DM, Gross M, Zhao L, Hassan MC, Arumugarajah S, Parsels JD, Hylander-Gans L, Simeone DM, Morosini D, Brown JL, Zabludoff SD, et al. Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition. Clin Cancer Res. 2011; 17:3706-15.
-
(2011)
Clin Cancer Res.
, vol.17
, pp. 3706-3715
-
-
Parsels, L.A.1
Qian, Y.2
Tanska, D.M.3
Gross, M.4
Zhao, L.5
Hassan, M.C.6
Arumugarajah, S.7
Parsels, J.D.8
Hylander-Gans, L.9
Simeone, D.M.10
Morosini, D.11
Brown, J.L.12
Zabludoff, S.D.13
-
27
-
-
84879437606
-
Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas
-
Shortt J, Martin BP, Newbold A, Hannan KM, Devlin JR, Baker AJ, Ralli R, Cullinane C, Schmitt CA, Reimann M, Hall MN, Wall M, Hannan RD, Pearson RB, McArthur GA, Johnstone RW. Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas. Blood. 2013; 121:2964-74.
-
(2013)
Blood.
, vol.121
, pp. 2964-2974
-
-
Shortt, J.1
Martin, B.P.2
Newbold, A.3
Hannan, K.M.4
Devlin, J.R.5
Baker, A.J.6
Ralli, R.7
Cullinane, C.8
Schmitt, C.A.9
Reimann, M.10
Hall, M.N.11
Wall, M.12
Hannan, R.D.13
Pearson, R.B.14
McArthur, G.A.15
Johnstone, R.W.16
-
28
-
-
74849091341
-
Pseudo-DNA damage response in senescent cells
-
Pospelova TV, Demidenko ZN, Bukreeva EI, Pospelov VA, Gudkov AV, Blagosklonny MV. Pseudo-DNA damage response in senescent cells. Cell Cycle. 2009; 8:4112-8.
-
(2009)
Cell Cycle.
, vol.8
, pp. 4112-4118
-
-
Pospelova, T.V.1
Demidenko, Z.N.2
Bukreeva, E.I.3
Pospelov, V.A.4
Gudkov, A.V.5
Blagosklonny, M.V.6
-
30
-
-
74849131381
-
When senescence masquerades as DNA damage: is DNA replication stress the culprit?
-
Darzynkiewicz Z. When senescence masquerades as DNA damage: is DNA replication stress the culprit?. Cell Cycle. 2009; 8:3810-1.
-
(2009)
Cell Cycle.
, vol.8
, pp. 3810-3811
-
-
Darzynkiewicz, Z.1
-
31
-
-
84880352272
-
Myc mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers
-
Pourdehnad M, Truitt ML, Siddiqi IN, Ducker GS, Shokat KM, Ruggero D. Myc mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers. Proc Natl Acad Sci U S A. 2013; 110:11988-93.
-
(2013)
Proc Natl Acad Sci U S A.
, vol.110
, pp. 11988-11993
-
-
Pourdehnad, M.1
Truitt, M.L.2
Siddiqi, I.N.3
Ducker, G.S.4
Shokat, K.M.5
Ruggero, D.6
-
32
-
-
84902083075
-
Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers
-
Cottini F, Hideshima T, Xu C, Sattler M, Dori M, Agnelli L, Hacken E, Bertilaccio MT, Antonini E, Neri A, Ponzoni M, Marcatti M, Richardson PG, Carrasco R, Kimmelman AC, Wong KK, Caligaris-Cappio F, Blandino G, Kuehl WM, Anderson KC, Tonon G. Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers. Nat Med. 2014; 20:599-606.
-
(2014)
Nat Med.
, vol.20
, pp. 599-606
-
-
Cottini, F.1
Hideshima, T.2
Xu, C.3
Sattler, M.4
Dori, M.5
Agnelli, L.6
Hacken, E.7
Bertilaccio, M.T.8
Antonini, E.9
Neri, A.10
Ponzoni, M.11
Marcatti, M.12
Richardson, P.G.13
Carrasco, R.14
Kimmelman, A.C.15
Wong, K.K.16
Caligaris-Cappio, F.17
Blandino, G.18
Kuehl, W.M.19
Anderson, K.C.20
Tonon, G.21
more..
-
33
-
-
9144237554
-
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
-
Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Müller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004; 103:275-82.
-
(2004)
Blood.
, vol.103
, pp. 275-282
-
-
Hans, C.P.1
Weisenburger, D.D.2
Greiner, T.C.3
Gascoyne, R.D.4
Delabie, J.5
Ott, G.6
Müller-Hermelink, H.K.7
Campo, E.8
Braziel, R.M.9
Jaffe, E.S.10
Pan, Z.11
Farinha, P.12
Smith, L.M.13
-
34
-
-
33744992010
-
Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score
-
Went P, Agostinelli C, Gallamini A, Piccaluga PP, Ascani S, Sabattini E, Bacci F, Falini B, Motta T, Paulli M, Artusi T, Piccioli M, Zinzani PL, et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol. 2006; 24:2472-2479.
-
(2006)
J Clin Oncol.
, vol.24
, pp. 2472-2479
-
-
Went, P.1
Agostinelli, C.2
Gallamini, A.3
Piccaluga, P.P.4
Ascani, S.5
Sabattini, E.6
Bacci, F.7
Falini, B.8
Motta, T.9
Paulli, M.10
Artusi, T.11
Piccioli, M.12
Zinzani, P.L.13
-
35
-
-
84868602463
-
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
-
Xu-Monette ZY, Wu L, Visco C, Tai YC, Tzankov A, Liu WM, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, et al. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2012; 120:3986-96.
-
(2012)
Blood.
, vol.120
, pp. 3986-3996
-
-
Xu-Monette, Z.Y.1
Wu, L.2
Visco, C.3
Tai, Y.C.4
Tzankov, A.5
Liu, W.M.6
Montes-Moreno, S.7
Dybkaer, K.8
Chiu, A.9
Orazi, A.10
Zu, Y.11
Bhagat, G.12
Richards, K.L.13
-
36
-
-
0027315157
-
Recent results on the biology of Hodgkin and Reed-Sternberg cells. II. Continuous cell lines
-
Drexler HG. Recent results on the biology of Hodgkin and Reed-Sternberg cells. II. Continuous cell lines. Leuk Lymphoma. 9; 13:1-25.
-
(2009)
Leuk Lymphoma.
, vol.13
, pp. 1-25
-
-
Drexler, H.G.1
-
37
-
-
73849145729
-
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
-
Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, Xu W, Shaffer AL, Wright G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010; 463:88-92.
-
(2010)
Nature.
, vol.463
, pp. 88-92
-
-
Davis, R.E.1
Ngo, V.N.2
Lenz, G.3
Tolar, P.4
Young, R.M.5
Romesser, P.B.6
Kohlhammer, H.7
Lamy, L.8
Zhao, H.9
Yang, Y.10
Xu, W.11
Shaffer, A.L.12
Wright, G.13
-
38
-
-
33845382806
-
Nonparametric estimations from incomplete observations
-
Kaplan EL, Meier P. Nonparametric estimations from incomplete observations. J Amer Statist Assn. 1958; 53:457-81.
-
(1958)
J Amer Statist Assn.
, vol.53
, pp. 457-481
-
-
Kaplan, E.L.1
Meier, P.2
-
39
-
-
84863948323
-
The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma
-
Derenzini E, Lemoine M, Buglio D, Katayama H, Ji Y, Davis RE, Sen S, Younes A. The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma. Blood Cancer J. 2011; 1:e46.
-
(2011)
Blood Cancer J.
, vol.1
-
-
Derenzini, E.1
Lemoine, M.2
Buglio, D.3
Katayama, H.4
Ji, Y.5
Davis, R.E.6
Sen, S.7
Younes, A.8
-
40
-
-
84859827198
-
The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines
-
Lemoine M, Derenzini E, Buglio D, Medeiros LJ, Davis RE, Zhang J, Ji Y, Younes A. The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines. Blood. 2012; 119:4017-25.
-
(2012)
Blood.
, vol.119
, pp. 4017-4025
-
-
Lemoine, M.1
Derenzini, E.2
Buglio, D.3
Medeiros, L.J.4
Davis, R.E.5
Zhang, J.6
Ji, Y.7
Younes, A.8
-
41
-
-
0028930859
-
Transcriptional repression by the C-terminal domain of p53
-
Shaulian E, Haviv I, Shaul Y, Oren M. Transcriptional repression by the C-terminal domain of p53. Oncogene. 1995; 10:671-80.
-
(1995)
Oncogene.
, vol.10
, pp. 671-680
-
-
Shaulian, E.1
Haviv, I.2
Shaul, Y.3
Oren, M.4
-
42
-
-
0025318790
-
A series of mammalian expression vectors and characterisation of their expression of a reporter gene in stably and transiently transfected cells
-
Morgenstern JP, Land H. A series of mammalian expression vectors and characterisation of their expression of a reporter gene in stably and transiently transfected cells. Nucleic Acids Res. 1990; 18:1068.
-
(1990)
Nucleic Acids Res.
, vol.18
, pp. 1068
-
-
Morgenstern, J.P.1
Land, H.2
|